From time to time, in one way or another, most of us can relate to having an inability to focus, being easily distracted, being poorly organized, and sometimes being impulsive. For those that suffer from ADHD, this can be an average day.
This can be problematic in day-to-day life and a person with ADHD has a higher risk of injury, depression, unemployment, imprisonment, and those with ADHD have a higher divorce rate than the average population.
On average 5-7% of children have ADHD (which is a disorder, not a disease) but this percentage decreases among adults, and historically ADHD has been very hard to accurately identify and diagnose, and can often be mislabelled and misattributed.
Fortunately, thanks to modern technology, the development of more accurate diagnoses are underway, and in today’s episode we will be speaking with Carl Reuterskiöld, CEO of Qbtech, a company giving healthcare professionals objective data to inform decisions about ruling in or ruling out ADHD.
Listen to this podcast on Spotify, Anchor, Apple Podcasts, Breaker, Google Podcasts, Stitcher, Overcast, Listen Notes, PodBean, and Radio Public.
To kick off the show, Reuterskiöld goes over exactly what ADHD is and how it can be identified. Reuterskiöld then explains how they can create an objective, unbias view for analyzing ADHD behavior in a patient using a camera and data. He also covers why the efficacy of treatments is hard to measure when diagnoses are based on subjective analysis.
He also shares how Qbtech began, how he joined the company, and how the work of Qbtech stands out from work previously produced in the space of ADHD research.
DARPA's O-Circuit program looks to build a new class of biologically inspired computer equipped with…
As AI races into classrooms worldwide, Google is finding that the toughest lessons on how…
The push to eat bugs is not an organic movement coming from the people, but…
As Africa’s digital economy accelerates, a new partnership between the Africa Digital Assets Summit 2026…
The State of Generative AI in the Enterprise report from Menlo Ventures found that companies…
Living therapies, made of engineered immune cells – and capable of hunting down cancer, reversing…